Clinical research

A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients

EuroIntervention 2013;8:1052-1060 published online ahead of print November 2012. DOI: 10.4244/EIJV8I9A162

Pascal Vranckx
Pascal Vranckx1,2, MD; Freek W.A. Verheugt3, MD, PhD; Moniek P. de Maat4, PhD; Victor A.W.M. Ulmans5, MD; Evelyn Regar6, MD, PhD; Peter Smits7, MD, PhD; Jurrien M. ten Berg8, MD, PhD; Wietze Lindeboom2, BSc; Russel L. Jones9, MSc; Jeffrey Friedman10, MD; Paul Reilly10, PhD; Frank W.G. Leebeek4*, MD, PhD
1. Department of Cardiac Intensive Care & Interventional Cardiology, Hartcentrum, Hasselt, Belgium; 2. Cardialysis, Clinical Research Management & Core Laboratories, Rotterdam, The Netherlands; 3. Department of Cardiology, Onze Lieve

Aims: Patients receiving long-term anticoagulant treatment with dabigatran may need to undergo a percutaneous coronary intervention (PCI

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

angioplastyanticoagulationcoronary artery diseasethrombosis
Read next article
Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularisation with drug-eluting stents

Latest news